Compare Gilead Sciences, Inc. (GILD) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Williams Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Williams Companies Inc's market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Williams Companies Inc for 58 Days on average.
| GILD | WMB | |
|---|---|---|
Market Cap | $182.40B | $88.48B |
Volume | 4,469,821 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $155.80 | $79.40 |
52-Week Low | $116.74 | $56.51 |
Typical Hold Time | 111 Days | 58 Days |
Enterprise Value | $205.46B | $119.11B |
Dividend Yield | 2.23% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Williams Companies (WMB) trades at $71.46, down 1.28% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company benefits from stable fee-based revenues in the midstream energy sector, positioning it well for AI-driven natural gas demand growth.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus target, offering 22% upside potential. Key opportunities include dividend growth strategy and exposure to rising natural gas demand from data centers. Risks include energy market volatility, high debt levels at 52% debt-to-asset ratio, and execution challenges in capital-intensive projects. The stock's valuation at 28.47 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
